about
Hypoxia and TGF-beta drive breast cancer bone metastases through parallel signaling pathways in tumor cells and the bone microenvironment.Actions of bisphosphonates in animal models of breast cancerThe haploinsufficient hematopoietic microenvironment is critical to the pathological fracture repair in murine models of neurofibromatosis type 1RhoGDI2 is an invasion and metastasis suppressor gene in human cancerAromatase inhibitor-induced bone loss increases the progression of estrogen receptor-negative breast cancer in bone and exacerbates muscle weakness in vivoThe TGF-β Signaling Regulator PMEPA1 Suppresses Prostate Cancer Metastases to BoneTumor-expressed adrenomedullin accelerates breast cancer bone metastasis.Role of bisphosphonates in prostate cancer bone metastases.Transforming growth factor-beta in osteolytic breast cancer bone metastases.Mechanisms of osteoblastic metastases: role of endothelin-1.Modulation of mammalian life span by the short isoform of p53.Halofuginone inhibits the establishment and progression of melanoma bone metastases.The reaction of bone to tumor growth from human breast cancer cells in a rat spine single metastasis model.RANKL/RANK/MMP-1 molecular triad contributes to the metastatic phenotype of breast and prostate cancer cells in vitroRegulation of postnatal trabecular bone formation by the osteoblast endothelin A receptor.Molecular biology and therapeutics in musculoskeletal oncology.TGF-beta-RI kinase inhibitor SD-208 reduces the development and progression of melanoma bone metastasesGLI2-mediated melanoma invasion and metastasis.Endothelins in bone cancer metastases.Molecular mechanisms of breast cancer metastases to bone.Breast cancer metastasis to bone: mechanisms of osteolysis and implications for therapy.Mechanisms and treatment for bone metastases.Advancing treatment for metastatic bone cancer: consensus recommendations from the Second Cambridge Conference.Cancer treatment-related bone disease.Advances in treating metastatic bone cancer: summary statement for the First Cambridge ConferenceDoes prostate-specific antigen contribute to bone metastases?Pharmacologic inhibition of the TGF-beta type I receptor kinase has anabolic and anti-catabolic effects on bone.The human Cyr61 gene is a transcriptional target of transforming growth factor beta in cancer cells.New insights into the role of T cells in the vicious cycle of bone metastases.Do markers of bone turnover predict clinical outcome in patients with bone metastases?Basic mechanisms responsible for osteolytic and osteoblastic bone metastases.Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formationBone loss and fracture risk associated with cancer therapy.BMP7: a new bone metastases prevention?Drug insight: the use of bisphosphonates for the prevention and treatment of osteoporosis in men.Breaking new ground to build boneSkeletal metastases: decreasing tumor burden by targeting the bone microenvironment.Cancer-associated bone disease.Molecular biology of bone metastasis.Local effects of malignancy on bone.
P50
Q21142766-C8D46E1E-6E3D-48EA-81B4-980E27A3DB30Q24802119-D224BD59-2B8A-498E-9315-E41207BDB255Q27319893-1B59CE92-4BB0-44B4-9CFD-56043516E568Q28215254-49D828BB-C291-4514-83D2-6D96DD50B34DQ30275126-D532FAF2-D24E-41AD-80BF-68DB5EE63E48Q30299930-0580C432-39EB-4EF5-94B7-FA1118B28DCCQ30301242-E3A015F5-3417-431F-A886-5C7ACDF252C1Q30311905-402997A8-A410-458D-8FAE-852DD27E4A55Q30311918-431FBA4D-53CC-4563-9D8F-57C3F5AE27AFQ30311986-C1554313-1136-4DE8-B8A2-3C392E9413DEQ30312095-1E52A75D-3317-4B28-AB33-2552494B535DQ30393926-2DCAE80B-4043-4F29-8322-3F8A00E9CF66Q30415248-02CFA4FF-5B15-4EF9-8F9C-E6E18EC66440Q30419245-73A3F2B5-74E0-4645-8E06-5A7610EE847FQ30424724-1ADB0C10-0313-4C12-8F92-313B54F72E56Q30426953-8B66F64E-B044-45CC-B7A6-FFDE081680DEQ30429041-5925AF93-68CC-4678-A3F3-D9350BA29AA1Q30431168-B1774D6B-54E2-46F7-874A-3AD1E915492EQ30433168-9125153C-ABFD-4089-9571-931D62450494Q30436458-69DA051B-CADB-485A-9AAB-8F7023A48DF6Q30437441-4F860D50-A73B-4FEC-9F7F-67018CBAB0EEQ30438051-FD93C5DC-0EA8-422C-9F32-DE346177A904Q30438167-A2F42DEF-464E-46F7-9CC3-AA61B388AA4EQ30438185-273E3B22-2A65-4A12-BDB6-4AAC4746D789Q30439259-B017B26E-E677-4D05-BF99-F322407D2FBBQ30439766-CE672C2C-AE12-4D7E-8C21-63F248397777Q30439859-A87B806B-F65A-46FB-90B3-B3056A3428C0Q30440228-F7A3060F-E24B-44D3-A1F4-46D7B6E1DADFQ30440690-3E8D3F68-EB99-4E16-94D8-B19AD7E3D27AQ30441407-8F66AAD6-9E83-43DE-9B87-7C8D3748674AQ30441961-6645D8B2-A5C5-4599-8018-E7C618C75EB7Q30441987-5B756998-EB8D-4472-B072-13821FCABCC8Q30442150-34526FDA-4AE1-4216-BDED-2473B4DDCA47Q30443506-AF0E9867-B303-4BB1-B7AF-F3FAC2281F05Q30443800-F461285B-A04A-43FE-B06A-D56BCBD5807EQ30443900-823BB717-AE3F-4BA0-80ED-BE9C759A3AE6Q30444637-01F9491C-D370-4200-9B61-A2988AB480B2Q30444698-04AB8AAA-3D02-4440-95CE-1D8717E5263DQ30444749-B02A259A-5ED4-4871-BDE6-EE95A161078BQ30444911-EAE68323-D87A-4035-9502-7D3BE1427E26
P50
name
Theresa A Guise
@ast
Theresa A Guise
@en
Theresa A Guise
@nl
type
label
Theresa A Guise
@ast
Theresa A Guise
@en
Theresa A Guise
@nl
prefLabel
Theresa A Guise
@ast
Theresa A Guise
@en
Theresa A Guise
@nl